Literature DB >> 29477204

MicroRNA-155 promotes neointimal hyperplasia through smooth muscle-like cell-derived RANTES in arteriovenous fistulas.

Ke Wang1, Peng Deng1, Yuan Sun2, Ping Ye3, Anchen Zhang3, Chuangyan Wu1, Zhang Yue1, Zhaolei Chen2, Jiahong Xia4.   

Abstract

OBJECTIVE: Arteriovenous fistula (AVF) suffers from a high number of failures caused by insufficient outward remodeling and venous neointimal hyperplasia formation. The aim was to investigate the exact mechanism by which microRNA-155 (miR-155) in the outflow vein of AVF is regulated.
METHODS: AVFs between the branch of the jugular vein and carotid artery in an end-to-end manner were created in C57BL/6 and miR-155-/- mice with a C57BL/6 background. The venous segments were harvested at day 7, 14, 21, and 28, and the AVFs were analyzed histologically and at a messenger RNA level using real-time quantitative polymerase chain reactions. The outflow vein of AVF and the normal great saphenous vein, collected from patients with chronic kidney disease and coronary artery bypass surgery, were analyzed by histologic and molecular biologic approaches.
RESULTS: Venous neointimal hyperplasia is significantly alleviated in miR-155-/- mice, and the expression of several chemokines and cytokines in the vessel wall, including regulated on activation, normal T-cell expressed and secreted factor (RANTES), monocyte chemoattractant protein 1, and vascular endothelial growth factor, was inhibited. miR-155 promoted the RANTES expression of smooth muscle-like cells, which in turn facilitated cell proliferation and extracellular matrix production.
CONCLUSIONS: miR-155 enhances venous neointima formation through the autocrine and paracrine effects of smooth muscle-like cell-derived RANTES in a nuclear factor κB-dependent manner during the entire AVF process, especially at the advanced stage.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29477204     DOI: 10.1016/j.jvs.2017.02.046

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  5 in total

Review 1.  Arteriovenous conduits for hemodialysis: how to better modulate the pathophysiological vascular response to optimize vascular access durability.

Authors:  Yan-Ting Shiu; Joris I Rotmans; Wouter Jan Geelhoed; Daniel B Pike; Timmy Lee
Journal:  Am J Physiol Renal Physiol       Date:  2019-02-20

2.  Systemic Profile of Cytokines in Arteriovenous Fistula Patients and Their Associations with Maturation Failure.

Authors:  Laisel Martinez; Mikael Perla; Marwan Tabbara; Juan C Duque; Miguel G Rojas; Nieves Santos Falcon; Simone Pereira-Simon; Loay H Salman; Roberto I Vazquez-Padron
Journal:  Kidney360       Date:  2022-01-13

3.  Nucleotide-Binding Oligomerization Domain-Like Receptor Protein 3 Deficiency in Vascular Smooth Muscle Cells Prevents Arteriovenous Fistula Failure Despite Chronic Kidney Disease.

Authors:  Xiangchao Ding; Jiuling Chen; Chuangyan Wu; Guohua Wang; Cheng Zhou; Shanshan Chen; Ke Wang; Anchen Zhang; Ping Ye; Jie Wu; Shanshan Chen; Hao Zhang; Kaiying Xu; Sihua Wang; Jiahong Xia
Journal:  J Am Heart Assoc       Date:  2019-01-08       Impact factor: 5.501

4.  Polyherbal formulation Anoac‑H suppresses the expression of RANTES and VEGF for the management of bleeding hemorrhoids and fistula.

Authors:  Ashwin Porwal; Gopal C Kundu; Gajanan Bhagwat; Ramesh Butti
Journal:  Mol Med Rep       Date:  2021-08-20       Impact factor: 2.952

Review 5.  The Effects of Pro-Inflammatory and Anti-Inflammatory Agents for the Suppression of Intimal Hyperplasia: An Evidence-Based Review.

Authors:  Rohaina Che Man; Nadiah Sulaiman; Mohamad Fikeri Ishak; Ruszymah Bt Hj Idrus; Mohd Ramzisham Abdul Rahman; Muhammad Dain Yazid
Journal:  Int J Environ Res Public Health       Date:  2020-10-26       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.